|
**Overview**: Anti-dsDNA Crithidia IFA Dilutions Panel**Introduction**: The Anti-dsDNA Crithidia IFA Dilutions Panel is a diagnostic tool designed to quantify anti-dsDNA antibodies for SLE diagnosis using serum samples. In India, systemic lupus erythematosus (SLE) affects approximately 3-10 per 100,000 population, with higher prevalence in women of reproductive age (female:male ratio 9:1), and significant underdiagnosis in rural and low-SES groups due to nonspecific symptoms and limited rheumatology access. Anti-dsDNA is a highly specific marker for SLE, correlating with disease activity, particularly lupus nephritis (present in 40-60 percent of cases). Symptoms include malar rash, photosensitivity, arthritis, renal involvement, and fatigue. High morbidity from delayed diagnosis leading to organ damage, renal failure, or mortality (5-year survival ~90 percent with treatment). Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs Crithidia luciliae immunofluorescence with dilutions for titer quantification over 1-2 days with high specificity, valuable for monitoring SLE activity and response to therapy. This diagnostic falls under autoimmune screening and targets patients with suspected or confirmed SLE, addressing accurate titer assessment to guide immunosuppressive treatment and prevent flares. With elevated morbidity due to underdiagnosis in diverse populations, the test supports public health efforts by enabling precise monitoring, facilitating management, and reducing long-term organ damage. Its serum-based approach ensures reliable performance in India's varied laboratory settings.**Other Names**: dsDNA IFA Dil Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Crithidia IFA introduced as gold standard for anti-dsDNA; in India, widely used in rheumatology clinics for SLE monitoring.**Purpose**: The test quantifies 2 parameters including anti-dsDNA titer to guide SLE diagnosis, assess disease activity, inform treatment adjustments.**Test Parameters**: 1. Anti-dsDNA (Crithidia), 2. Anti-dsDNA Titer.**Pretest Condition**: No fasting required; patients should report joint pain, rash, renal symptoms, fatigue, or known SLE.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on SLE symptoms, renal involvement, treatment history, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated SLE including renal failure, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunofluorescence by trained personnel to ensure sterile technique, avoid hemolysis, and interpret titers within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High titers indicate active SLE, necessitating treatment escalation. Low/negative results may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists should be consulted for case management, treatment planning.**Additional Supporting Tests**: Complement levels, urine analysis, or biopsy for confirmation.**Test Limitations**: Titers may fluctuate or require correlation with clinical activity; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, SLE Studies India 2023. |
